In ALL, genes in the relevant signaling pathways were downregulated in the mutation group, whereas in AML, they were upregulated, highlighting the differing roles of FLT3 mutations in the development of these leukemias. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.